US7393682B1
(en)
|
1993-03-19 |
2008-07-01 |
The Johns Hopkins University School Of Medicine |
Polynucleotides encoding promyostatin polypeptides
|
US5925362A
(en)
*
|
1993-08-11 |
1999-07-20 |
Jenner Technologies |
Method to elicit an antitumor response with human prostate-specific antigen
|
US7354587B1
(en)
|
1994-07-06 |
2008-04-08 |
Immunomedics, Inc. |
Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
|
US5798100A
(en)
*
|
1994-07-06 |
1998-08-25 |
Immunomedics, Inc. |
Multi-stage cascade boosting vaccine
|
ATE235514T1
(de)
*
|
1994-12-28 |
2003-04-15 |
Univ Kentucky |
Monoklonaler anti-idiotypischer antikörper 3h1 aus maus
|
US6949244B1
(en)
|
1995-12-20 |
2005-09-27 |
The Board Of Trustees Of The University Of Kentucky |
Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
|
US5763216A
(en)
*
|
1995-06-07 |
1998-06-09 |
The United States Of America As Represented By The Department Of Health & Human Services |
Gene encoding a human reduced folate carrier (RFC)
|
US5716788A
(en)
*
|
1995-06-07 |
1998-02-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Antibodies to human reduced folate carrier protein
|
EP2057999A3
(de)
|
1995-12-22 |
2009-07-29 |
Immunomedics, Inc. |
Verwendung von immunokonjugaten zur erhöhung der effektivität von mehrstufigen kaskaden-impfstoffen
|
US6730300B2
(en)
|
1996-03-20 |
2004-05-04 |
Immunomedics, Inc. |
Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
|
US6235280B1
(en)
|
1996-04-12 |
2001-05-22 |
Malaya Chatterjee |
Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
|
US20020041872A1
(en)
|
1996-04-12 |
2002-04-11 |
Malaya Chatterjee |
Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
|
EP1007569B1
(de)
|
1997-02-11 |
2009-04-08 |
Immunomedics, Inc. |
Stimulation einer immunantwort durch antikörper, welche mit dem alpha-galaktosylepitop markiert sind
|
US6306393B1
(en)
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
US6183744B1
(en)
|
1997-03-24 |
2001-02-06 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
US6274143B1
(en)
|
1997-06-13 |
2001-08-14 |
Malaya Chatterjee |
Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
|
US6891082B2
(en)
|
1997-08-01 |
2005-05-10 |
The Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a truncated activintype II receptor
|
KR20080009171A
(ko)
*
|
1997-08-13 |
2008-01-24 |
더 유에이비 리서치 파운데이션 |
유전자 벡터의 국소 적용에 의한 백신접종
|
AU2994599A
(en)
*
|
1998-03-06 |
1999-09-20 |
Imclone Systems Incorporated |
Active immunization against angiogenesis-associated antigens
|
US6652836B2
(en)
|
1998-10-15 |
2003-11-25 |
Fluoroprobe, Inc. |
Method for viewing tumor tissue located within a body cavity
|
DK1133558T4
(en)
|
1998-11-27 |
2016-05-17 |
Ucb Sa |
Compositions and methods for increasing bone mineralization
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
US7833529B1
(en)
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
WO2000040716A2
(en)
|
1999-01-07 |
2000-07-13 |
Zymogenetics, Inc. |
Soluble receptor br43x2 and methods of using them for therapy
|
EP1194167B1
(de)
|
1999-06-09 |
2009-08-19 |
Immunomedics, Inc. |
Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
|
IL147336A0
(en)
|
1999-07-07 |
2002-08-14 |
Zymogenetics Inc |
Human cytokine receptor
|
CA3016482A1
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
RU2172182C1
(ru)
*
|
2000-07-27 |
2001-08-20 |
Бритов Василий Александрович |
Способ профилактики и лечения заболеваний иммунной системы и средство для его осуществления
|
WO2002036578A2
(en)
|
2000-10-31 |
2002-05-10 |
Lynn Bonham |
Triazine derivatives as lpaat-b inhibitors and uses thereof
|
US6890734B2
(en)
|
2000-11-10 |
2005-05-10 |
Schering Corporation |
Nucleic acids encoding a cytokine receptor complex
|
WO2002066516A2
(en)
|
2001-02-20 |
2002-08-29 |
Zymogenetics, Inc. |
Antibodies that bind both bcma and taci
|
AT410637B
(de)
*
|
2001-06-01 |
2003-06-25 |
Igeneon Krebs Immuntherapie |
Verwendung von polyklonalen immunglobulinen
|
US7291616B2
(en)
|
2001-10-31 |
2007-11-06 |
Cell Therapeutics, Inc. |
Aryl triazines as LPAAT-β inhibitors and uses thereof
|
US8877901B2
(en)
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
MXPA05003049A
(es)
|
2002-09-19 |
2005-11-17 |
Us Gov Health & Human Serv |
Polipeptidos de phlebotomus ariasi, polipeptidos de phlebotomus perniciosus y metodos de uso.
|
US7419984B2
(en)
|
2002-10-17 |
2008-09-02 |
Cell Therapeutics, Inc. |
Pyrimidines and uses thereof
|
EP1572968B1
(de)
|
2002-10-29 |
2009-04-22 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Lutzomyia longipalpis-polypeptide und verwendungsverfahren
|
US6875781B2
(en)
|
2003-04-04 |
2005-04-05 |
Cell Therapeutics, Inc. |
Pyridines and uses thereof
|
US20110020273A1
(en)
*
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
US7901680B2
(en)
|
2005-10-19 |
2011-03-08 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) vaccines for cancer therapy
|
US8491914B2
(en)
*
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
US8562988B2
(en)
|
2005-10-19 |
2013-10-22 |
Ibc Pharmaceuticals, Inc. |
Strategies for improved cancer vaccines
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
US20110064754A1
(en)
*
|
2005-03-03 |
2011-03-17 |
Center For Molecular Medicine And Immunology |
Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
|
US8435539B2
(en)
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
GB0412966D0
(en)
|
2004-06-10 |
2004-07-14 |
Univ Leicester |
Genetically modified non-human mammals and cells
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
PL1753456T3
(pl)
|
2004-06-10 |
2017-01-31 |
Omeros Corporation |
Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2
|
AU2005295038B2
(en)
|
2004-10-06 |
2012-05-17 |
Mayo Foundation For Medical Education And Research |
B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
|
AU2006212807A1
(en)
|
2005-02-08 |
2006-08-17 |
Zymogenetics, Inc. |
Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
|
JP5214252B2
(ja)
|
2005-03-03 |
2013-06-19 |
イミューノメディクス、インコーポレイテッド |
ヒト化l243抗体
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
US20070054360A1
(en)
|
2005-05-12 |
2007-03-08 |
Zeren Gao |
Compositions and methods for modulating immune responses
|
WO2006128715A2
(en)
*
|
2005-06-03 |
2006-12-07 |
Widnes Company Inc. |
Polyclonal antiserum against a universal tumor antigen
|
JP2009507777A
(ja)
|
2005-08-09 |
2009-02-26 |
ザイモジェネティクス,インコーポレイティド |
TACI−Ig融合分子を用いたB細胞性腫瘍の処置方法
|
EP1922079A2
(de)
|
2005-08-09 |
2008-05-21 |
ZymoGenetics, Inc. |
Verfahren zur behandlung und prävention abnormaler zellproliferation mittels taci-fusionsmolekülen
|
EP2674440B1
(de)
|
2005-12-16 |
2019-07-03 |
IBC Pharmaceuticals, Inc. |
Polyvalente bioaktive anordnungen auf immunglobulinbasis
|
WO2007082352A1
(en)
|
2006-01-20 |
2007-07-26 |
Child Health Research Institute Inc |
Method of treatment, prophylaxis and diagnosis of pathologies of the bone
|
EP2275816A3
(de)
|
2006-03-22 |
2011-06-29 |
Viral Logic Systems Technology Corp. |
Verfahren zur Identifizierung von Polypeptid-targets und ihre Verwendung zur Behandlung von Immunerkrankungen
|
US8377448B2
(en)
|
2006-05-15 |
2013-02-19 |
The Board Of Trustees Of The Leland Standford Junior University |
CD47 related compositions and methods for treating immunological diseases and disorders
|
US8784812B2
(en)
|
2006-05-15 |
2014-07-22 |
Zymogenetics, Inc. |
Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
|
WO2008088582A2
(en)
|
2006-08-04 |
2008-07-24 |
Mayo Foundation For Medical Education And Research |
Methods and materials related to trail isoforms
|
ES2629440T5
(es)
|
2007-10-04 |
2020-11-20 |
Zymogenetics Inc |
zB7H6 miembro de la familia B7 y composiciones y métodos relacionados
|
EP2570137A3
(de)
*
|
2007-11-07 |
2013-08-21 |
Celldex Therapeutics, Inc. |
Antikörper zur Bindung von humaner dendritischer und Epithelzelle 205 (DEC-205)
|
US8859230B2
(en)
|
2007-11-21 |
2014-10-14 |
Roskilde Universitet |
Polypeptides comprising an ice-binding activity
|
US8552155B2
(en)
|
2008-05-28 |
2013-10-08 |
Mayo Foundation For Medical Education And Research |
Anti-Pyk2 antibodies
|
CN102448494B
(zh)
|
2009-02-13 |
2016-02-03 |
免疫医疗公司 |
具有胞内可裂解的键的免疫共轭物
|
ES2566361T3
(es)
|
2009-07-02 |
2016-04-12 |
Massachusetts Institute Of Technology |
Composiciones y métodos para diagnosticar y/o tratar una infección gripal
|
EP2456787A4
(de)
|
2009-07-24 |
2013-01-30 |
Univ Leland Stanford Junior |
Zytokinzusammensetzungen und verfahren zu ihrer verwendung
|
MX344322B
(es)
|
2009-10-16 |
2016-12-13 |
Omeros Corp |
Uso de una composición que comprende un agente inhibidor de masp-2 efectivo para inhibir o prevenir la aparición de agregados en la vaculatura de un sujeto que sufre de un desorden de coagulación mediado por complemento.
|
WO2011055550A1
(ja)
|
2009-11-05 |
2011-05-12 |
国立大学法人大阪大学 |
自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
|
EP2582717A2
(de)
|
2010-06-15 |
2013-04-24 |
Vertex Pharmaceuticals Incorporated |
Hcv-ns5b-polymerasemutanten
|
US8802110B2
(en)
|
2010-09-21 |
2014-08-12 |
Massachusetts Institute Of Technology |
Influenza treatment and/or characterization, human-adapted HA polypeptides; vaccines
|
US10226527B2
(en)
|
2010-10-04 |
2019-03-12 |
Massachusetts Institute Of Technology |
Hemagglutinin polypeptides, and reagents and methods relating thereto
|
US20140308242A1
(en)
|
2010-10-21 |
2014-10-16 |
Vertex Pharmaceuticals Incorporated |
Biomarkers for hcv infected patients
|
WO2012057765A1
(en)
|
2010-10-28 |
2012-05-03 |
The Board Of Regents Of The University Of Texas System |
Recombinant anti-cd19 monoclonal antibodies
|
NZ746139A
(en)
|
2011-04-08 |
2023-11-24 |
Omeros Corp |
Methods for treating conditions associated with masp-2 dependent complement activation
|
US9644035B2
(en)
|
2011-04-08 |
2017-05-09 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
CN103648526A
(zh)
|
2011-06-17 |
2014-03-19 |
田纳西大学研究基金会 |
A群链球菌多价疫苗
|
EP2788020A4
(de)
|
2011-12-05 |
2015-04-29 |
Immunomedics Inc |
Therapeutische verwendung von anti-cd22-antikörpern zur induktion von trogozytose
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
US9421250B2
(en)
|
2012-03-23 |
2016-08-23 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pathogenic phlebovirus isolates and compositions and methods of use
|
HUE036930T2
(hu)
|
2012-04-06 |
2018-08-28 |
Omeros Corp |
Készítmények és eljárások MASP-1 és/vagy MASP-3 gátlására paroxymalis nocturnalis hemoglobinürítés kezelésére
|
SG11201406769RA
(en)
|
2012-05-10 |
2014-11-27 |
Massachusetts Inst Technology |
Agents for influenza neutralization
|
IN2015KN00015A
(de)
|
2012-06-18 |
2015-07-31 |
Omeros Corp |
|
WO2014015217A1
(en)
|
2012-07-19 |
2014-01-23 |
Vertex Pharmaceuticals Incorporated |
Biomarkers for hcv infected patients
|
CA2874864C
(en)
|
2012-08-14 |
2023-02-21 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
WO2017004144A1
(en)
|
2015-07-01 |
2017-01-05 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
WO2015012904A2
(en)
|
2012-12-13 |
2015-01-29 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
PL2900277T3
(pl)
|
2012-12-13 |
2022-05-16 |
Immunomedics, Inc. |
Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
EP2948471A4
(de)
|
2013-01-24 |
2016-08-10 |
Mayo Foundation |
Verfahren und materialien zur erkennung der positiven frontotemporallappen-degeneration durch c9orf72-hexanukleotid-repeat-expansion oder von amyotropher lateralsklerose durch c9orf72-hexanukleotid-repeat-expansion
|
CA2898633C
(en)
|
2013-02-07 |
2021-07-13 |
Massachusetts Institute Of Technology |
Human adaptation of h5 influenza
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
CN105209633A
(zh)
|
2013-03-14 |
2015-12-30 |
夏尔人类遗传性治疗公司 |
信使rna加帽效率的定量评估
|
EP2999484B1
(de)
|
2013-05-23 |
2019-09-11 |
Shire Human Genetic Therapies, Inc. |
Anti-ccl2- und anti-loxl2-kombinationstherapie zur behandlung von sklerodermie
|
WO2014197723A2
(en)
|
2013-06-05 |
2014-12-11 |
Massachusetts Institute Of Technology |
Human adaptation of h7 ha
|
WO2014202089A2
(en)
|
2013-06-18 |
2014-12-24 |
Roskilde Universitet |
Variants of anti-freeze polypeptides
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
ES2714708T3
(es)
|
2013-10-01 |
2019-05-29 |
Mayo Found Medical Education & Res |
Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
|
RU2020111211A
(ru)
|
2013-10-17 |
2021-11-08 |
Омерос Корпорейшн |
Способы лечения состояний, ассоциированных с masp-2-зависимой активацией комплемента
|
US20150174242A1
(en)
|
2013-12-19 |
2015-06-25 |
Mayo Foundation For Medical Education And Research |
Monovalent anti-cd3 adjuvants
|
WO2015130416A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
EP3560954B1
(de)
|
2014-04-03 |
2021-08-04 |
IGM Biosciences, Inc. |
Modifizierte j-kette
|
US9833512B2
(en)
|
2014-04-09 |
2017-12-05 |
Mayo Foundation For Medical Education And Research |
Blocking IL-9 signaling in conjunction with chemotherapy to treat cancer
|
WO2015179654A1
(en)
|
2014-05-22 |
2015-11-26 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti b7-h1 antibodies
|
JP2017525675A
(ja)
|
2014-07-09 |
2017-09-07 |
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ |
回旋筋腱板異常の処置
|
EP3171896A4
(de)
|
2014-07-23 |
2018-03-21 |
Mayo Foundation for Medical Education and Research |
Abzielung auf dna-pkcs und b7-h1 zur behandlung von krebs
|
CN106999517A
(zh)
|
2014-10-07 |
2017-08-01 |
免疫医疗公司 |
抗体‑药物缀合物的新辅助剂用途
|
US20180057588A1
(en)
|
2015-03-16 |
2018-03-01 |
Aarhus Universitet |
Antibodies Towards an Extracellular Region of NBCn1
|
JP6746845B2
(ja)
|
2015-04-22 |
2020-08-26 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
循環trop−2陽性癌細胞の単離、検出、診断及び/または特徴付け
|
CN107735104B
(zh)
|
2015-06-25 |
2022-05-03 |
免疫医疗公司 |
组合抗hla-dr抗体或抗trop-2抗体与微管抑制剂、parp抑制剂、布鲁顿激酶抑制剂或磷酸肌醇3-激酶抑制剂使癌症治疗结果显著改善
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
EP3322481A4
(de)
|
2015-07-16 |
2019-03-06 |
Mayo Foundation for Medical Education and Research |
Behandlung von rotatormanschettenleiden
|
WO2017075045A2
(en)
|
2015-10-30 |
2017-05-04 |
Mayo Foundation For Medical Education And Research |
Antibodies to b7-h1
|
WO2017083371A1
(en)
|
2015-11-09 |
2017-05-18 |
Omeros Corporation |
Methods for treating conditions associated with masp-2 dependent complement activation
|
WO2017117130A1
(en)
|
2015-12-28 |
2017-07-06 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
|
IL294411A
(en)
|
2016-01-05 |
2022-08-01 |
Omeros Corp |
masp-2 suppressors for use in suppressing fibrosis
|
CN108601841A
(zh)
|
2016-02-10 |
2018-09-28 |
免疫医疗公司 |
Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
|
AU2017240129B2
(en)
|
2016-03-31 |
2020-04-02 |
Omeros Corporation |
Methods for inhibiting angiogenesis in a subject in need thereof
|
EP3448260A4
(de)
|
2016-04-27 |
2019-10-09 |
Immunomedics, Inc. |
Wirksamkeit von anti-trop-2-sn-38-antikörper-wirkstoff-konjugaten zur therapie von rezidivierten/refraktären tumoren gegen checkpoint-inhibitoren
|
EP4245775A3
(de)
|
2016-04-29 |
2023-11-15 |
Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. |
Multispezifisches bindungskonjugat, entsprechende pharmazeutische zusammensetzungen und verwendung
|
WO2018055031A1
(en)
|
2016-09-21 |
2018-03-29 |
Aarhus Universitet |
Acid-base transport inhibitors
|
EP3600283A4
(de)
|
2017-03-27 |
2020-12-16 |
Immunomedics, Inc. |
Behandlung von trop-2-exprimierendem triple-negativem brustkrebs mit sacituzumab govitecan und einem rad51-hemmer
|
WO2018187074A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
TW202402809A
(zh)
|
2017-08-15 |
2024-01-16 |
美商歐米諾斯公司 |
用於治療和/或預防與造血幹細胞移植有關的移植物抗宿主病和/或瀰漫性肺泡出血和/或靜脈閉塞性病的方法
|
JP7241069B2
(ja)
|
2017-09-25 |
2023-03-16 |
フレッド ハッチンソン キャンサー センター |
高効率標的in situゲノムワイドプロファイリング
|
US11768205B2
(en)
|
2017-11-06 |
2023-09-26 |
Mayo Foundation For Medical Education And Research |
Methods and materials for identifying and treating cancers having elevated levels of phosphorylated ubiquitin
|
US11584714B2
(en)
|
2018-05-29 |
2023-02-21 |
Omeros Corporation |
MASP-2 inhibitors and methods of use
|
IL293550A
(en)
|
2019-12-04 |
2022-08-01 |
Omeros Corp |
2-masp inhibitor compounds, preparations containing them and their uses
|
AU2021226341A1
(en)
|
2020-02-25 |
2022-09-29 |
Mediboston Limited |
Camptothecin derivatives and conjugates thereof
|
KR20230104611A
(ko)
|
2020-09-30 |
2023-07-10 |
드렌 바이오, 인크. |
항-cd94 항체 및 이의 사용 방법
|
US20240108744A1
(en)
|
2022-07-27 |
2024-04-04 |
Mediboston Limited |
Auristatin derivatives and conjugates thereof
|